Department of Pathology, Kyungpook National University Chilgok Hospital, Kyubgpook National University, Daegu, Republic of Korea.
Department of Gastroenterology, Kyungpook National University Chilgok Hospital, Kyubgpook National University, Daegu, Republic of Korea.
In Vivo. 2024 Nov-Dec;38(6):2904-2911. doi: 10.21873/invivo.13772.
BACKGROUND/AIM: Endoscopic submucosal dissection (ESD) effectively treats selected early gastric cancers (EGCs). However, the association of microsatellite instability (MSI), Epstein-Barr virus (EBV), p53, and β-catenin status with clinicopathologic parameters in EGCs treated with ESD have not been well studied.
We retrospectively collected 312 consecutive EGC cases treated with ESD from January 2021 to December 2023 at Kyungpook National University Chilgok Hospital. MSI polymerase chain reaction, EBV encoded RNA in situ hybridization, and p53 and β-catenin immunostaining were performed for all cases.
Among 312 EGC cases, there were 42 MSI-High (MSI-H) cases (13.5%), 13 EBV-associated gastric cancer (EBVaGC) cases (4.2%), 249 intestinal type cases (79.8%), and eight poorly cohesive carcinoma cases (2.6%). MSI-H was significantly associated with lymphovascular invasion (p=0.02), local recurrence (p=0.03), and synchronous tumors (p<0.001). More than half of EBVaGC cases showed submucosal invasion (61.5%, 8/13) (p=0.016). Consequently, non-curative ESD was more frequently found in EBVaGC than in other subtypes (p<0.001). Mutant p53 patterns and nuclear translocation of β-catenin were almost exclusively found in the intestinal type (p<0.001), without association with clinicopathologic parameters. Margin involvement was frequent in poorly cohesive carcinoma (p=0.003).
We demonstrated that MSI-H and EBVaGC are strongly associated with clinicopathologic parameters and risk factors in EGCs treated with ESD. Molecular testing of gastric cancers should be considered before ESD for better patient management.
背景/目的:内镜黏膜下剥离术(ESD)可有效治疗某些早期胃癌(EGC)。然而,在接受 ESD 治疗的 EGC 中,微卫星不稳定性(MSI)、Epstein-Barr 病毒(EBV)、p53 和 β-连环蛋白状态与临床病理参数之间的关联尚未得到很好的研究。
我们回顾性收集了 2021 年 1 月至 2023 年 12 月在庆北大学 Chilgok 医院接受 ESD 治疗的 312 例连续 EGC 病例。对所有病例均进行 MSI 聚合酶链反应、EBV 编码 RNA 原位杂交以及 p53 和 β-连环蛋白免疫染色。
在 312 例 EGC 病例中,有 42 例 MSI 高度不稳定(MSI-H)病例(13.5%)、13 例 EBV 相关胃癌(EBVaGC)病例(4.2%)、249 例肠型病例(79.8%)和 8 例低黏附性癌病例(2.6%)。MSI-H 与淋巴管浸润(p=0.02)、局部复发(p=0.03)和同步肿瘤(p<0.001)显著相关。超过一半的 EBVaGC 病例表现为黏膜下浸润(61.5%,8/13)(p=0.016)。因此,EBVaGC 比其他亚型更常出现非治愈性 ESD(p<0.001)。突变型 p53 模式和β-连环蛋白核转位几乎仅见于肠型(p<0.001),与临床病理参数无关。低黏附性癌的边缘受累较为常见(p=0.003)。
我们证实,MSI-H 和 EBVaGC 与接受 ESD 治疗的 EGC 患者的临床病理参数和危险因素密切相关。在进行 ESD 之前,应考虑对胃癌进行分子检测,以便更好地进行患者管理。